CLINICAL STUDY RESULTS
A Study about 4 Different Dosing Regimens of Ravulizumab in
Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
who Never had Treatment with a Complement Inhibitor
THANK YOU!
Alexion would like to thank
all of the patients, their families, and
caregivers who took part in this
clinical study. Taking part in studies
like this one contributes directly to
the discovery of new medicines for
people with PNH.
STUDY IDENTIFICATION INFORMATION
TREATMENT STUDIED: Ravulizumab, also known as ALXN1210 (trade name: Ultomiris®)
STUDY TITLE: A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability,
Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered
Intravenously to Patients with Paroxysmal Nocturnal Hemoglobinuria.
STUDY NUMBERS: Europe, 2015-002674-20 | United States, NCT02605993 | Protocol, ALXN1210-PNH-201
© Certara USA, Inc. 2020. All rights reserved 1